Natno Biotechl: New technology for highly sensitive detection of COVID-19.

27, 2020 // --- In a recent study published in the journal Nature Biotechnology, scientists from the National Duke University School of Medicine worked closely with the National Center for Infectious Diseases (NCID), the Singapore Institute of Molecular and Cell Biology (IMCB), to develop a new test kit, "sVNT."
sVNT can detect the presence of functional neutralizing antibodies (NAb) in newly coronavirus-infected people, preventing the binding of the coronavirus stingin synthasi and angiotensin-converting enzyme 2 (ACE2) host receptor.
scientists in Singapore and China validated the trial in two patient queues, with 250 samples in China and 375 in Singapore with a specificity of 99-100% and sensitivity of 95-100%.
(picture: www.pixabay.com) sVNT kits can detect functional NAb within an hour and distinguish it by binding antibodies (BAb) without the presence of a live virus.
, contrary to most of the same-specific SARS-CoV-2 antibody tests that have been released or sold, it also has the ability to detect neutralizing antibodies in the targeted total receptor binding domain (RBD) in patient samples.
critical time for the international community's response to the COVID-19 outbreak, there is an urgent need for a robust serological testtomime to detect NAb to accurately assess infection rates and protective immunity in individuals and populations.
antibody testing, such as routine virus neutraltesting (cVNT) and pseudo-virus-based virus neutraltesting (pVNT), remain the only platform for detecting NAb.
, however, both require live viruses and cells, and a few days to get results.
other assay, such as enzyme-linked immunosorption assays (ELISA), do not distinguish between neutral and nodule antibodies.
"The question of how many proportions of patients with COVID-19 can produce antibodies against COVID-19, how long it lasts and whether the antibodies can protect patients from reinfection, has become an increasingly critical clinical issue."
neutralizing antibodies is the gold standard serological platform that determines this.
unfortunately, conventional virus neutralization is laborious, time-consuming, and requires a high biosecurity rating of COVID-19.
the research co-developed sVNT, which can be used by all hospital laboratories, and has made significant progress in COVID-19 serological testing, the sVNT kit is commercialized by GenScript and is available worldwide under the cPass ™ brand for research use only.
GenScript has also applied to the U.S. Food and Drug Administration (FDA) for an emergency use authorization and is currently reviewing the document.
(Bioon.com) Information Source: Scientists Develop COVID-19 test to thorifi neutral lys with with high-rhy, specificity original source: Tan, C. W., et al. (2020) A SARS-CoV-2. Nature Biotechnology. doi.org/10.1038/s41587-020-0631-z.